The latest data on youth tobacco use in the United States reveal a public health success story that often goes unnoticed: tobacco use among young people has fallen to historically low levels. This progress is not accidental; it stems from years of prevention efforts, stricter age restrictions, public education, and a collective commitment to keeping nicotine products away from minors. Yet, despite this encouraging trend, the challenge of adult cigarette smoking persists, and a balanced approach is needed to address both issues simultaneously.
According to the CDC, cigarette smoking remains the leading cause of preventable death in the United States, with millions of adults continuing to smoke despite decades of warnings and restrictions. While quitting entirely is always the best health choice, for adults who would otherwise continue smoking, access to accurate information about smoke-free nicotine alternatives is crucial. This is where the FDA's recent decision on ZYN nicotine pouches becomes significant.
After a thorough scientific review, the FDA issued modified risk orders for 20 ZYN nicotine pouch products, permitting them to be marketed with the authorized claim that using ZYN instead of cigarettes reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. The agency did not declare these products safe or encourage non-users to start; rather, it authorized a claim to help adult smokers understand the relative risks. This distinction is vital: nicotine products are addictive and not risk-free, but science-based policy should acknowledge the meaningful differences in harm between combustible cigarettes and smoke-free alternatives for adults who switch completely.
The latest youth tobacco data from the FDA's 2025 National Youth Tobacco Survey underscore that protecting youth and providing adult alternatives are not mutually exclusive. The survey shows declines in current use of tobacco products, combustible tobacco products, and e-cigarettes between 2022 and 2025. Nicotine pouch use among youth remained low and stable, with 1.7 percent of students reporting current use in 2025, compared to 1.8 percent in 2024. These figures should instill confidence, not complacency, demonstrating that low youth use can coexist with FDA-authorized smoke-free products for adults.
PMI U.S., the company behind ZYN, has emphasized that its smoke-free nicotine products are intended for current nicotine consumers aged 21 and older—not youth, non-users, or those trying to quit nicotine altogether. The company's responsible marketing practices reflect this commitment: advertising features individuals aged 35 or older, websites require independent age verification for visitors 21 and older, and social media presence is limited to platforms with age-restricted controls. PMI U.S. does not pay social media influencers or engage in product placement in movies or TV shows. These practices are part of a 10-point approach to underage prevention that includes age-gated websites, monitoring underage-use data, responsible marketing standards, retail support, and enforcement against illicit products.
No single entity can address this alone. The right strategy is practical and evidence-based: keep nicotine products away from anyone under 21, enforce minimum age laws, tackle illicit products, maintain clear product standards, and require responsible marketing. The United States has made significant strides in reducing youth tobacco use, and it is time to apply the same seriousness to helping adult smokers transition to better alternatives. A mature tobacco policy can do both: prevent young people from starting and assist adults who continue to smoke in moving to lower-risk options. These goals are complementary and essential for public health.
